Menold Daniel 4
4 · CymaBay Therapeutics, Inc. · Filed Dec 15, 2023
Insider Transaction Report
Form 4
Menold Daniel
Vice President, Finance
Transactions
- Exercise/Conversion
Common Stock
2023-12-15$4.05/sh+10,000$40,500→ 10,000 total - Sale
Common Stock
2023-12-15$21.98/sh−10,000$219,847→ 0 total - Exercise/Conversion
Common Stock
2023-12-15$8.43/sh+11,497$96,920→ 11,497 total - Sale
Common Stock
2023-12-15$21.99/sh−11,497$252,799→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-12-15−10,000→ 145,109 totalExercise: $4.05Exp: 2030-05-14→ Common Stock (10,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2023-12-15−11,497→ 0 totalExercise: $8.43Exp: 2029-01-28→ Common Stock (11,497 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.70 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The shares subject to the option vest in 48 equal monthly installments commencing on January 31, 2020.
- [F5]The shares subject to the option vest as to 1/4 of the underlying shares on January 1, 2020, and vest as to 1/48 of the underlying shares monthly thereafter.